(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 82.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.4%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Kura Oncology's revenue in 2025 is $67,991,000.On average, 5 Wall Street analysts forecast KURA's revenue for 2025 to be $13,412,150,510, with the lowest KURA revenue forecast at $2,545,295,798, and the highest KURA revenue forecast at $28,933,260,395. On average, 5 Wall Street analysts forecast KURA's revenue for 2026 to be $19,500,082,500, with the lowest KURA revenue forecast at $2,744,417,578, and the highest KURA revenue forecast at $39,062,498,774.
In 2027, KURA is forecast to generate $38,990,641,784 in revenue, with the lowest revenue forecast at $4,882,812,347 and the highest revenue forecast at $101,179,836,697.